FDA APPROVES TEVA'S GENERIC DESFERAL

A A

Teva Pharmaceutical has announced that the FDA has granted approval for the company's abbreviated new drug application for deferoxamine mesylate for injection, in 500 mg vials and 2 g vials.

Deferoxamine mesylate for injection is the generic equivalent of Novartis' Desferal for injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias.